ost clinical trial teams within pharmaceutical companies want to design studies that work for patients. Trial protocols are often built on assumptions about what will reduce patients’ burden, what patients would be willing to accept, or which endpoints truly matter. These assumptions are usually well-meant, but when they are wrong, the consequences can be costly: slow recruitment, amendments, drop-outs, and frustrated participants.

Over the past several years, one large pharmaceutical company moved from ad hoc patient engagement toward a systematic approach to incorporating patient input into trial design. This was driven by a dedicated team within the Clinical Development & Operations department, established in 2021, and reflected the collective efforts of more than 700 staff involved in the design and conduct of clinical trials.

Five years into this transformation, we performed a retrospective analysis of the company’s portfolio to ask the following question: Does early, structured patient input translate into measurable operational benefit?

What We Analyzed

The analysis included interventional clinical trials initiated after January 1, 2021. Trials spanned phases 1–3, with the majority in phases 2 and 3, across inflammation, cardiometabolic, oncology, respiratory, dermatology, eye health, and mental health indications. Thirty-seven trials were grouped based on whether patient input had been incorporated into the trial design or not; some trials were included in multiple analyses below.

• Recruitment speed analysis: 37 trials with completed recruitment; 24 of those trials incorporated patient input into trial design.
• Protocol amendment analysis: 17 completed trials; 9 of those trials incorporated patient input into trial design. Trials where amendments were driven by positive data and/or scope expansion were excluded.
• Drop-out rates analysis: 16 completed trials; 8 of those trials incorporated patient input into trial design.

This was a retrospective, observational analysis. Recruitment speed, amendments, and retention are influenced by many factors; patient input was assessed as one contributing factor. No individual trial, indication, or asset is identified.

How Patient Input Was Generated: Why and When It Matters

Patient input was not collected informally or late in the process. Insights were generated before protocol finalization, primarily prior to the trial design freeze, using a combination of:

• Trial simulations allowing patients to walk through draft trial concepts, followed by structured interviews.
• Structured interviews and patient advisory boards exploring burden drivers and feasibility.
• The number of insights grew substantially over time, and to avoid asking patients the same questions over and over again, an AI-powered chatbot was introduced later to summarize existing insights ahead of new patient engagements.

What the Data Showed: Patient Input Paid Off

Faster recruitment: Trials that incorporated patient input into design recruited on average 31% faster, corresponding to approximately 205 days earlier completion of recruitment per trial compared with trials without such input.

Using conservative, industry-standard estimates of daily trial costs across phases, this difference corresponds to potential estimated cost savings of approximately €24 million per trial, excluding the downstream value of earlier access to market. Since recruitment speed is influenced by many factors, the actual cost savings from patient input into trial design are likely not 100% of this estimate.

Fewer protocol amendments: Trials with early patient input had 1.6 fewer global protocol amendments on average than those without input.

Avoiding a single global amendment not only reduces direct amendment costs but also helps prevent timeline delays. Together, this translates into €11.5 million of potential savings per trial, again excluding downstream effects. Since amendments are influenced by many factors, the actual cost savings from patient input into trial design are likely not 100% of this estimate.

Lower drop-out rates: Across the analyzed portfolio, trials with patient input showed on average an 8.3% lower patient drop-out rate (9.8% for trials with patient input versus 18.1% for those without), corresponding to a relative reduction of 46.1%. Retention improvements reduce the need for overenrollment and protect data quality.

A critical insight emerged over time: Engaging patients too late limits impact. In several early experiences, patient feedback identified meaningful study challenges; however, the protocol was already frozen, and changes were no longer possible without delaying the trial start. As a result, understanding patient needs before trial design is locked became a non-negotiable requirement and a key performance indicator for all the company’s trials.

Four Lessons Learned from Moving to Systematic Patient Input

1. Don’t assume you know what patients need. In one trial, teams invested significant effort and budget into home nursing services that they believed would reduce burden, only to find that patients did not use them at all. Assumptions, even well-intentioned ones, often miss the mark.

2. Start very early. In one trial, the selected endpoint did not capture the patient experience and potential improvements in a meaningful way. However, we only asked for input three weeks before the trial started, and changes were no longer possible without delaying the trial start. Patient input has its greatest value when it informs endpoints, visit structure, and procedures before the trial design freeze—decisions that are difficult or impossible to change later.

3. Make patient centricity everyone’s responsibility. Historically, patient feedback has sometimes been gathered by specialists and handed off to busy trial planning teams, where it competed with other priorities. Embedding accountability for addressing patient needs directly within the roles that are designing and conducting the trials ensured that insights translated into decisions rather than reports.

4. Leadership commitment matters. Adoption accelerated markedly after senior leaders explicitly prioritized patient input in R&D objectives. Visible leadership support transformed engagement from an optional activity into expected practice.

Trial Examples

Several recurring design challenges illustrate how patient input translated into concrete improvements:

• Dermatology trial: Patient input revealed that prohibiting standard pain comedication created a major participation barrier. Allowing appropriate pain treatments removed this obstacle without compromising trial integrity.
• Rheumatology trial: Patient feedback identified skin imaging procedures that did not work well for patients with darker skin tones. Alternative imaging methods and targeted site training improved both inclusivity and data quality.

In each case, relatively modest design adjustments—made early—helped avoid downstream delays and rework.

Good Intentions are Not Enough

Why this matters for the industry
Recruitment challenges, protocol amendments, and patient drop-outs are widely documented as major drivers of delay and cost inefficiency in clinical development. At the same time, regulators increasingly expect sponsors to demonstrate that patient perspectives meaningfully inform trial design.

This experience suggests that patient input is imperative. When applied systematically and early, it functions as a form of risk prevention, identifying friction before it becomes expensive to fix. Importantly, these benefits were observed across therapeutic areas and trial phases, not in isolated pilots.

Turning Intent into Impact

For organizations seeking similar outcomes, three principles stand out:

1. Engage patients before trial designs are frozen, not after.
2. Use structured, repeatable methods, rather than ad hoc feedback.
3. Link patient input to operational outcomes, not just trial experience metrics. For example, feedback from pulmonary fibrosis patients stated that they face challenges reaching sites (e.g., traveling with oxygen), so solutions like concierge support or offering ePRO options can significantly reduce the burden.

The shift from assumptions to evidence does not eliminate uncertainty in drug development, but it significantly reduces avoidable friction. In an environment where speed, quality, and trust all matter, systematic patient input is increasingly becoming less a “nice to have” and more a strategic necessity.